PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of medThis ArticleSubmit a manuscriptThis Journal
 
Open Med (Wars). 2016; 11(1): 477–481.
Published online 2016 November 19. doi:  10.1515/med-2016-0084
PMCID: PMC5329871

Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer

Abstract

Conventional transbronchial needle aspiration (C-TBNA) is a minimally invasive technique used primarily in the diagnosis and staging of lung cancer. Currently lung cancer is mostly considered a disease of the elderly and the management of this disease in older patients is a growing concern.

In this study we aimed to assess the diagnostic yield and safety of C-TBNA in elderly patients.

A retrospective review of 88 consecutive C-TBNA procedures for nodal staging in suspected or confirmed primary lung cancer or pathological confirmation in suspected advanced lung cancer was performed. Patients were divided into less than 70 (<70yrs) or 70 and older (≥70yrs) age groups for analysis. There were no significant differences either in the diagnostic yield (69% in patients aged < 70 yrs and 74% patients aged ≥ 70 yrs (p=0.5) nor in the complication rate (respectively 8.8% in patients aged < 70 yrs and 6.9% in patients aged ≥ 70 yrs (p=0.7) between the two age groups. Reported complications were minor bleeding and poor tolerance; no major complications were observed.

Based on our experience, C-TBNA represents a useful and safe alternative procedure for the diagnosis and staging of lung cancer in elderly patients.

Keywords: Bronchoscopy, Transbronchial needle aspiration – TBNA, lung cancer, elderly

1. Introduction

Conventional transbronchial needle aspiration (C-TBNA or TBNA) is a minimally invasive technique used to obtain diagnostic samples from peribronchial or submucosally located lesions [1-43]. For over 30 years, until the introduction of endobronchial ultrasound guided (EBUS)-TBNA, conventional TBNA was considered the standard bronchoscopic modality for the evaluation of undiagnosed mediastinal lymphadenopathy [1-43].

C-TBNA can be used in various pathological conditions but is used primarily for obtaining mediastinal or hilar lymph node tissue for the diagnosis and staging of bronchogenic carcinoma [1-43].

Lung cancer is one of the leading causes of cancer deaths worldwide. It is mostly considered a disease of the elderly: the median age at diagnosis is 70 years and the incidence of lung cancer increases with age [29]. Data from cancer statistics revealed that in United States in 2011, 82 % of those living with lung cancer were 60 years of age or older [30].

Currently, the management of lung cancer in older patients is a growing concern, particularly with the increase of elderly population [29,30].

Accurate staging is crucial to evaluate the most appropriate therapy and the prognosis of lung cancer. Although the recent advancements in imaging modalities, such as computed tomography (CT) and positron emission tomography (PET), have drastically improved the detection and evaluation of lung cancer, these non-invasive methods do not provide definitive disease confirmation and have limitations in nodal staging.

A meta-analysis of both CT (sensitivity 51%) and PET scan (sensitivity 75%) showed relatively low sensitivity for the detection of nodal metastases, underlining the importance of pathological nodal staging [31].

Until recently, mediastinoscopy has been the “gold standard” to establish mediastinal involvement. However the use of mediastinoscopy, performed in an operative suite under general anesthesia, is potentially limited in older patients with concomitant diseases.

Several studies assessed the usefulness and safety of C-TBNA in diagnosis and staging of lung cancer; however data about the efficacy of this procedure in elderly populations are scant.

In the present study, we aimed to assess the diagnostic yield and safety of C-TBNA in older patients.

2. Patients and methods

We performed a retrospective review of 88 consecutive C-TBNA procedures for nodal staging in suspected or confirmed primary lung cancer or pathological confirmation in suspected advanced lung cancer.

All the procedures were performed on an inpatient basis, in the bronchoscopy unit at San Giovanni di Dio e Ruggi d’Aragona Hospital of Salerno from 2010 to 2015.

The procedures were done as part of the routine clinical care. Informed consent for the procedure was obtained from all the patients. Ethical approval for the study was not required as the intervention and data collection form part of our standard clinical care.

For every patient undergoing C-TBNA, a systematic examination of mediastinum was performed and criteria for sampling a lymph node were the following: a short axis greater than 10 mm on CT or abnormal nodal fluorodeoxyglucose avidity above that of the mediastinal blood pool on PET-CT.

Flexible bronchoscopy was performed through the nasal route, using the Olympus BF TE2 bronchofiberscope (Olympus, Japan) with a 2.8 mm working channel. For patient preparation, local anesthesia included application of 2% lignocaine jelly nasally along with spray application of lignocaine over the pharynx and vocal cords prior to and during insertion of the flexible bronchoscope. All the procedures were performed under conscious sedation. In patients over 70 years, mean doses of sedation were lower. Respiratory rate, heart rate, and pulse oximetric oxygen saturation was monitored throughout during the procedure.

Rapid on-site cytology examination (ROSE) was not available.

Cytological samples were considered diagnostic if results revealed malignant cells or polymorphous lymphocytes without any other findings (reactionary lymph node). Cytological samples were considered not diagnostic if results revealed inadequate cytological material or only bronchial epithelial cells, mucus, or blood elements.

3. Results

Overall 88 patients underwent C-TBNA. Patients were divided into less than 70 (<70 yrs) or 70 and older (≥70 yrs) age categories for analysis. Most of patients were male (74/88, 84%) and mean age was 68.3 ± 10.4 years (range, 43–83 years). 45 patients were less than 70 years (51.3%) and 43 (48.8%) were 70yrs or older. 14 patients were aged over 80 yrs. We evaluated the efficacy in nodal staging and pathological confirmation in advanced disease and the safety of C- TBNA.

The unpaired t-test was used to detect difference between data.

Overall the diagnostic yield of 88 procedures was 71.5% (63/88). The diagnostic yield was 69% (31/45) in the group of patients < 70 yrs and 74% (32/43) in the group of patients ≥ 70 yrs (p=0.5).

A specific diagnosis was made in 60% (27/45) of patients < 70 yrs and in 65% (28/43) of patients ≥ 70 yrs (p 0.6)

Apart from minor bleeding at biopsy sites, no major complication (significant bleeding, pneumothorax or pneumomediastinum) occurred due to C-TBNA. Overall three cases of poor tolerance were reported in the two age cohorts. No complications were recorded in the 14 patients aged over 80 years. There was no statistically significant difference in complication rate between the two age cohorts (8,8% (4/45) in patients aged < 70 yrs and 6.9% (3/43) in patients aged ≥ 70 yrs (p= 0.7)).

Results are reported in Table 1.

Table 1

Table of Results

4. Discussion

The aim of this study was to evaluate the diagnostic yield and the safety of C-TBNA in elderly patients (defined as ≥ 70 yrs to correspond to the median age of lung cancer diagnosis and a common cut off point in clinical trials). The diagnostic yield of C-TBNA varies considerably among various studies. As reported in American College of Chest Physician 2013 guidelines (ACCP), mean sensitivity of C-TBNA for lung cancer was 76%, ranging from 14 to 100%. C-TBNA had a higher diagnostic yield for malignancy (64.7%) compared to non-malignant diseases (17.6%) [34, 35]. Nevertheless there are few data about efficacy and safety of this procedure in elderly patients with lung cancer.

In our study the diagnostic yield of 88 procedures was 73% overall. No significant difference in diagnostic yield was seen according to age threshold in the two groups, 69% in the group of patients aged less 70 years and 74% in the group of patients older than 70 yrs (p=0.5).

Not all results were verified with invasive methods such as mediastinoscopy or surgery due to different reasons such as a high rate of patient comorbidities, poor performance status, patient or family preference; as consequence, it’s likely that this group might contain false negative diagnoses, since C-TBNA is just a diagnostic procedure with a low sensitivity, but very high specificity [36].

Recently a large prospective study has demonstrated that EBUS-TBNA is a safe and well-tolerated procedure in elderly patients with lung cancer; nevertheless the additional training required and higher costs of this procedure prevent its routine use in all bronchoscopy centers [37]. Conventional TBNA is generally a safe procedure with a reported low incidence of complications. Potential complications are bleeding (severe bleeding occurs even after a major vessel puncture, a rarely reported event), pneumothorax or pneumomediastinum. In a meta-analysis of Holty et al., overall major complication rate (two major bleeds and one pneumothorax requiring chest tube) was 0.26% [37]. Other reported complications after C-TBNA procedures are fever, bacteremia and hemomediastinum [38, 39].

In our study no major complications occurred due to C-TBNA. As minor complications, minor bleeding and poor tolerance were reported, and their incidence wasn’t significantly different between the two age cohorts (respectively 8.8% in the group of patients aged less 70 years and 6.9% in the group of patients older than 70 yrs (p=0.7).

Based on our experience, C-TBNA should be considered a safe and efficacious procedure in diagnosis and staging of lung cancer before other more invasive procedures such as mediastinoscopy or surgery in elderly patients.

This study has several limitations: it’s a retrospective study, results didn’t include any comparison between C-TBNA results with invasive pathological sampling methods like mediastinoscopy or thoracotomy and analyses were mainly done to evaluate sampling success, thus adequate samples without any specific diagnoses may require further diagnostic procedures.

5. Conclusions

The management of lung cancer in the elderly is a current issue. Despite lung cancer being mostly considered a disease of the elderly, several studies show that older patients obtain lower histological confirmation rates, less accurate staging, and lower rates of definitive treatments than younger patients [40-43]. These differences are probably due to the perception that older patients might not be able to withstand invasive techniques and treatment.

In our study C-TBNA has been proven to be a safe and efficacious procedure in elderly patients with suspected or confirmed lung cancer. Recently EBUS-TBNA has been proven to be safe and well-tolerated in older patients however this procedure can be used more difficulty routinely since it is more complicated, requires additional training and has higher costs.

Based on our experience, C-TBNA still represents a very useful and safe alternative procedure for the diagnosis and staging of lung cancer in elderly patients.

6. Conflict of interest statement

Authors state no conflict of interest.

References

[1] Wang K.P., Terry P.B.. Transbronchial needle aspiration in the diagnosis and staging of bronchogenic carcinoma. Am. Rev. Respir. Dis. 1983;127:344–347. [PubMed]
[2] Yang H., Zhang Y., Wang K.-P., Ma Y.. Transbronchial needle aspiration: development history, current status and future perspective. J Thorac Dis. 2015;7:S279–286. [PMC free article] [PubMed]
[3] Wallace MB, Pascual JM, Raimondo M. et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA. 2008;299:540–546. [PubMed]
[4] Hermens F.H.W., Van Engelenburg T.C.A., Visser F.J., Thunnissen F.B.J.M., Termeer R., Janssen J.P.. Diagnostic yield of transbronchial histology needle aspiration in patients with mediastinal lymph node enlargement. Respiration. 2003;70:631–635. [PubMed]
[5] Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Maselli R.. Cellular mechanisms underlying eosinophilic and neutrophilic air way inflammation in asthma. Mediators Inflamm. 2015;2015:879783. [PMC free article] [PubMed]
[6] Pelaia G, Terracciano R, Vatrella A, Gallelli L, Busceti MT, Calabrese C, Stellato C, Savino R, Maselli R.. Application of proteomics and peptidomics to COPD. Biomed Res Int. 2014;2014:764581. [PMC free article] [PubMed]
[7] D’Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, Molino A, Vatrella A, D’Amato M.. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidiscip Respir Med. 2014;9(1):23. Apr 15. [PMC free article] [PubMed]
[8] Gallelli L, Busceti MT, Vatrella A, Maselli R, Pelaia G.. Update on anticytokine treatment for asthma. Biomed Res Int. 2013;2013:104315. [PMC free article] [PubMed]
[9] Vatrella A, Montagnani S, Calabrese C, Parrella R, Pelaia G, Biscione GL, Corcione N, Marsico SA, Guerra G.. Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents. 2010;24(4):425–432. Oct-Dec. [PubMed]
[10] Vatrella A, Ponticiello A, Pelaia G, Parrella R, Cazzola M.. Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Pulm Pharmacol Ther. 2005;18(2):89–92. [PubMed]
[11] Cozzolino I, Varone V, Picardi M, Baldi C, Memoli D, Ciancia G, Selleri C, De Rosa G, Vetrani A, Zeppa P.. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. Cancer Cytopathol. 2016;124(2):135–43. doi: 10.1002/cncy.21626. Feb. Epub 2015 Sep 28. PubMed PMID: 26414904. [PubMed] [Cross Ref]
[12] Cozzolino I, Vigliar E, Todaro P, Peluso AL, Picardi M, Sosa Fernandez LV, Mignogna MD, Tuccari G, Selleri C, Zeppa P.. Fine needle aspiration cytology of lymphoproliferative lesions of the oral cavity. Cytopathology. 2014;25(4):241–9. doi: 10.1111/cyt.12132. Aug. Epub 2014 Feb 7. PubMed PMID: 24750323. [PubMed] [Cross Ref]
[13] Vigliar E, Cozzolino I, Picardi M, Peluso AL, Fernandez LV, Vetrani A, Botti G, Pane F, Selleri C, Zeppa P.. Lymph node fine needle cytology in the staging and follow-up of cutaneous lymphomas. BMC Cancer. 2014;14:8. doi: 10.1186/1471-2407-14-8. Jan 6. PubMed PMID: 24393425; PubMed Central PMCID: PMC3890503. [PMC free article] [PubMed] [Cross Ref]
[14] Zeppa P, Sosa Fernandez LV, Cozzolino I, Ronga V, Genesio R, Salatiello M, Picardi M, Malapelle U, Troncone G, Vigliar E.. Immunoglobulin heavy-chain fluorescence in situ hybridization-chromogenic in situ hybridization DNA probe split signal in the clonality assessment of lymphoproliferative processes on cytological samples. Cancer Cytopathol. 2012;120(6):390–400. doi: 10.1002/cncy.21203. Dec 25. Epub 2012 Apr 19. PubMed PMID: 22517675. [PubMed] [Cross Ref]
[15] Peluso AL, Cascone AM, Lucchese L, Cozzolino I, Ieni A, Mignogna C, Pepe S, Zeppa P.. Use of FTA cards for the storage of breast carcinoma nucleic acid on fine-needle aspiration samples. Cancer Cytopathol. 2015;123(10):582–92. doi: 10.1002/cncy.21577. Oct. Epub 2015 Jun 29. PubMed PMID: 26123795. [PubMed] [Cross Ref]
[16] Zeppa P, Barra E, Napolitano V, Cozzolino I, Troncone G, Picardi M, De Renzo A, Mainenti PP, Vetrani A, Palombini L.. Impact of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in lymph nodal and mediastinal lesions: a multicenter experience. Diagn Cytopathol. 2011;39(10):723–9. doi: 10.1002/dc.21450. Oct. Epub 2010 Oct 19. PubMed PMID: 20960473. [PubMed] [Cross Ref]
[17] Cozzolino I, Vigliar E, Sosa Fernandez LV, Selleri C, Pepe S, Vitale M, Triggiani M, Zeppa P.. Non lymphomatous clonal B-Cell populations in enlarged lymph nodes in acquired immunodeficiency syndrome. Infez Med. 2012;20(suppl 2):35–42. [PubMed]
[18] Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Di Somma C, Orio F, Palomba S, Lombardi G, Rotoli B, Colao A.. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med. 2005;118(6):664–670. Jun. [PubMed]
[19] Fiorelli A, Mazzone S, Di Crescenzo VG, Costa G, Del Prete A, Vicidomini G, Mazzone A, Santini M.. A simple technique to control placement of Dumon stent in subglottic tracheal stenosis. Interact Cardiovasc Thorac Surg. 2014;18(3):390–2. doi: 10.1093/icvts/ivt504. Mar. Epub 2013 Dec 9. [PMC free article] [PubMed] [Cross Ref]
[20] Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Garzi A, Vitale M.. An unusual case of primary choriocarcinoma of the lung. BMC Surg. 2013;13(Suppl 2):S33. doi: 10.1186/1471-2482-13-S2-S33. Epub 2013 Oct 8. [PMC free article] [PubMed] [Cross Ref]
[21] Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Danzi M, Amato B, Garzi A, Vitale M.. Migration of surgical clips through a right lobectomy stump mimicking an asthmatic syndrome. BMC Surg. 2013;13(Suppl 2):S32. doi: 10.1186/1471-2482-13-S2-S32. Epub 2013 Oct 8. [PMC free article] [PubMed] [Cross Ref]
[22] Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Garzi A, Vitale M.. Pulmonary sequestration presented as massive left hemothorax and associated with primary lung sarcoma. BMC Surg. 2013;13(Suppl 2):S34. doi: 10.1186/1471-2482-13-S2-S34. Epub 2013 Oct 8. [PMC free article] [PubMed] [Cross Ref]
[23] Santini M, Fiorelli A, Messina G, Laperuta P, Mazzella A, Accardo M.. Use of the LigaSure device and the Stapler for closure of the small bowel: a comparative ex vivo study. Surg Today. 2013;43(7):787–93. doi: 10.1007/s00595-012-0336-0. jul. Epub 2012 Sep 15. [PubMed] [Cross Ref]
[24] Di Crescenzo V, Vitale M, Valvano L, Napolitano F, Vatrella A, Zeppa P, De Rosa G, Amato B, Laperuta P.. Surgical management of cervico-mediastinal goiters: Our experience and review of the literature. Int J Surg. 2016;28(Suppl 1):S47–53. doi: 10.1016/j.ijsu.2015.12.048. Apr. Epub 2015 Dec 23. [PubMed] [Cross Ref]
[25] Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Orio F Jr, Palomba S, Bifulco G, Nappi C, Lombardi G, Rotoli B, Colao A.. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod. 2003;18(7):1410–1416. Jul. [PubMed]
[26] Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Leoni P, Bacigalupo A.. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood. 2013;122(25):4111–4118. Dec 12. [PubMed]
[27] Selleri C, Maciejewski JP, Montuori N, Ricci P, Visconte V, Serio B, Luciano L, Rotoli B.. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood. 2003;102(4):1490–1498. Aug 15. [PubMed]
[28] Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S, Ciceri F, Fanin R, Rambaldi A, Falda M, Milone G, Guidi S, Martelli MF, Mazza P, Oneto R, Bosi A, Foà R, Leoni P, Liso V, Pioltelli P, Cascavilla N, Scimé R, Rizzoli V, Ballestrero A, Raimondi R, Arcese W, Musso M, Benedetti F, Guerrasio A, Majolino I, Lambertenghi DG, Baccarani M, Bacigalupo A, Petrini M, Carella AM, Levis A, La Nasa G, Merli F, Narni F, Lauria F, Cortelazzo S, Longinotti M, Olivieri A, Favre C, Cantore N, Da Prada GA, Selleri C, Bruno B, Giovanni M, Leone G, Di Bartolomeo P, Morandi S, Vallisa D.. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol. 2012;91(6):931–939. Jun. [PubMed]
[29] Howlader N NA, Krapcho M, Neyman N. et al. SEER Cancer Statistics Review, 1975-2009. http://seer.cancer.gov/csr/1975_2009_pops09/2011 Available at.
[30] U. S. National Institutes of Health. National Cancer Institute. SEER Cancer Statistics Review. :1975–2011.
[31] Silvestri GA, Gould MK, Margolis ML. et al. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition) Chest. 2007;132(3 Suppl):178S–201S. [PubMed]
[32] Öztürk Ö., Sandal A., Karahan S., Er B., Önder S., Köksal D., Maden E., Emri S.. Diagnostic yield of conventional transbronchial needle aspiration biopsy (C-TBNA) without an on-site cytopathologist: Experience of 363 procedures in 219 patients. Tuberk Toraks. 2016;64:137–1431. [PubMed]
[33] Patel N.M., Pohlman A., Husain A., Noth I., Hall J.B., Kress J.P.. Conventional transbronchial needle aspiration decreases the rate of surgical sampling of intrathoracic lymphadenopathy. Chest. 2007;131:773–778. [PubMed]
[34] Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123:157S–166S. [PubMed]
[35] Bonifazi M., Zuccatosta L., Trisolini R., Moja L., Gasparini S.. Transbronchial needle aspiration: a systematic review on predictors of a successful aspirate. Respiration. 2013;86:123–134. [PubMed]
[36] Holty JE1, Kuschner WG, Gould MK.. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis. Thorax. 2005;60(11):949–55. Nov. Epub 2005 Jun 30. [PMC free article] [PubMed]
[37] Evison M, Crosbie PA, Martin J, Bishop P, Doran H, Joseph L, Chaturvedi A, Barber PV, Booton R.. EBUS-TBNA in elderly patients with lung cancer: safety and performance outcomes. J Thorac Oncol. 2014;9(3):370–6. doi: 10.1097/JTO.0000000000000085. Mar. [PubMed] [Cross Ref]
[38] Witte MC, Opal SM, Gilbert JG. et al. Incidence of fever and bacteremia following transbronchial needle aspiration. Chest. 1986;89:85–87. [PubMed]
[39] Kucera RF, Wolfe GK, Perry ME.. Hemomediastinum after transbronchial needle aspiration. Chest. 1986;90:466. [PubMed]
[40] Brown JS, Eraut D, Trask C. et al. Age and the treatment of lung cancer. Thorax. 1996;51:564–568. [PMC free article] [PubMed]
[41] Janssen-Heijnen ML, Schipper RM, Razenberg PP. et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998;21:105–113. [PubMed]
[42] Connolly CK, Crawford SM, Rider PL. et al. Carcinoma of the bronchus in the Yorkshire region of England 1976–1990: trends since 1984. Eur Respir J. 1997;10:397–403. [PubMed]
[43] Muers MF, Round CE.. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993;48:339–343. [PMC free article] [PubMed]

Articles from Open Medicine are provided here courtesy of De Gruyter Open